Andrew is a brain scientist seeking to bridge the gap between basic and applied research. With a keen eye for win-win opportunity, he has led worldwide research collaborations, chaired preeminent conferences, and has advised companies both for-profit and not.
As Fractional CEO of Zafer Tx, he oversees corporate strategy, partnerships, and fundraising to advance Zafer’s platform from preclinical proof-of-concept in lupus-inspired models to first-in-human studies in ANCA-associated vasculitis.
Andrew is a Senior Consultant at Wave Strategy LLC and Owner/Principal of Cap Consulting LLC. Previously, he was CEO of 4P-Pharma USA, and Director of Biology at Convelo Therapeutics. He did his Postdoctoral training in Clinical Neurosciences at the University of Calgary Cumming School of Medicine (Canada). He holds a PhD in Physiology & Biophysics from Case Western Reserve University and a BA in Neuroscience from Oberlin College.
Individuals representing a university's TTO and a spinout negotiate a fictional license agreement in real time (including equity, royalties, milestones, sub-licensing rights, and milestone expectations) giving the audience an inside look at the strategy, tension, and tradeoffs behind university innovation deals. The session runs two scenarios, one pharma and one digital health.
